Phase II
Epygenix Therapeutics, Inc. announced that the Company successfully completed a Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to assess safety and pharmacokinetics of escalating single and multiple oral doses of EPX-100 in fasting healthy subjects and following a high-fat meal.
Habib Dable, president and chief executive officer of Acceleron, said he was “thrilled” about the positive results from the mid-stage PULSAR trial.
In addition to various deal news, AstraZeneca had clinical trial news today as well.
There were plenty of clinical trial announcements this week. Here’s a look.
As the J.P. Morgan Healthcare Conference winds down for 2020, one of the big topics was the general lack of big deals. Still, there were some general trends and for today, some news.
Companies from across the globe provide updates to their business and pipeline.
With the J.P. Morgan Healthcare Conference in full swing, companies did not waste time in announcing deals and providing updates to their pipelines. BioSpace takes a look at some of the announcements made on day one of the annual conference in the Bay Area.
The first full business week of the new year began with plenty of clinical trial news. Here’s a look.
Not waiting for the start of the annual J.P. Morgan Healthcare Conference, Eli Lilly announced it will acquire California-based Dermira, Inc. in an all-cash deal for $1.1 billion.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
PRESS RELEASES